• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Guideline adherence in antithrombotic treatment after concomitant ablation surgery in atrial fibrillation patients.房颤患者同期消融术后抗栓治疗的指南依从性
Interact Cardiovasc Thorac Surg. 2014 Mar;18(3):313-20. doi: 10.1093/icvts/ivt522. Epub 2013 Dec 13.
2
Improved outcomes with European Society of Cardiology guideline-adherent antithrombotic treatment in high-risk patients with atrial fibrillation: a report from the EORP-AF General Pilot Registry.欧洲心脏病学会指南指导下的抗栓治疗改善了高危房颤患者的预后:来自 EORP-AF 一般试点登记处的报告。
Europace. 2015 Dec;17(12):1777-86. doi: 10.1093/europace/euv269. Epub 2015 Aug 30.
3
Guideline adherence of antithrombotic treatment initiated by general practitioners in patients with nonvalvular atrial fibrillation: a Danish survey.丹麦调查:全科医生启动的非瓣膜性心房颤动患者抗栓治疗的指南遵循情况。
Clin Cardiol. 2013 Jul;36(7):427-32. doi: 10.1002/clc.22133. Epub 2013 May 13.
4
Evaluation of Adherence to Guideline-Directed Antithrombotic Therapy for Atrial Fibrillation at Hospital Discharge.出院时房颤患者遵循指南指导的抗栓治疗情况评估。
J Cardiovasc Pharmacol Ther. 2018 Nov;23(6):502-508. doi: 10.1177/1074248418778804. Epub 2018 May 27.
5
Outcomes of Patients With Atrial Fibrillation Newly Recommended for Oral Anticoagulation Under the 2014 American Heart Association/American College of Cardiology/Heart Rhythm Society Guideline.2014 年美国心脏协会/美国心脏病学会/心律学会指南新推荐口服抗凝治疗的心房颤动患者的结局。
J Am Heart Assoc. 2018 Jan 4;7(1):e007881. doi: 10.1161/JAHA.117.007881.
6
Adherence to antithrombotic therapy guidelines improves mortality among elderly patients with atrial fibrillation: insights from the REPOSI study.遵循抗血栓治疗指南可改善老年房颤患者的死亡率:来自REPOSI研究的见解。
Clin Res Cardiol. 2016 Nov;105(11):912-920. doi: 10.1007/s00392-016-0999-4. Epub 2016 May 31.
7
Adherence to Anticoagulant Guideline for Atrial Fibrillation Improves Outcomes in Asian Population: The COOL-AF Registry.抗凝治疗房颤指南在亚洲人群中的应用改善了结局:COOL-AF 注册研究。
Stroke. 2020 Jun;51(6):1772-1780. doi: 10.1161/STROKEAHA.120.029295. Epub 2020 May 11.
8
Stroke-prevention strategies in North American patients with atrial fibrillation: The GLORIA-AF registry program.北美心房颤动患者的卒中预防策略:GLORIA-AF注册研究项目
Clin Cardiol. 2018 Jun;41(6):744-751. doi: 10.1002/clc.22936. Epub 2018 May 10.
9
Contemporary Trends in Oral Anticoagulant Prescription in Atrial Fibrillation Patients at Low to Moderate Risk of Stroke After Guideline-Recommended Change in Use of the CHADS to the CHADS-VASc Score for Thromboembolic Risk Assessment: Analysis From the National Cardiovascular Data Registry's Outpatient Practice Innovation and Clinical Excellence Atrial Fibrillation Registry.在采用CHADS-VASc评分替代CHADS评分进行血栓栓塞风险评估的指南推荐更改后,低至中度卒中风险心房颤动患者口服抗凝药处方的当代趋势:来自国家心血管数据注册中心门诊实践创新与临床卓越心房颤动注册研究的分析
Circ Cardiovasc Qual Outcomes. 2017 May;10(5). doi: 10.1161/CIRCOUTCOMES.116.003476.
10
Flaws in Anticoagulation Strategies in Patients With Atrial Fibrillation at Hospital Discharge.房颤患者出院时抗凝策略的缺陷。
J Cardiovasc Pharmacol Ther. 2019 May;24(3):225-232. doi: 10.1177/1074248418821712. Epub 2019 Jan 1.

引用本文的文献

1
Exploring the Perioperative Use of DOACs, off the Beaten Track.探索非传统路径下直接口服抗凝剂的围手术期应用
J Clin Med. 2024 May 24;13(11):3076. doi: 10.3390/jcm13113076.
2
Management of Patients Treated with Direct Oral Anticoagulants in Clinical Practice and Challenging Scenarios.临床实践及复杂情况下接受直接口服抗凝剂治疗患者的管理
J Clin Med. 2023 Sep 13;12(18):5955. doi: 10.3390/jcm12185955.
3
Utilization of Anticoagulants in Nonvalvular Atrial Fibrillation Before and After Catheter Ablation at Shanghai, China.中国上海非瓣膜性心房颤动患者导管消融术前、后抗凝药物的使用情况
Clin Appl Thromb Hemost. 2019 Jan-Dec;25:1076029619826260. doi: 10.1177/1076029619826260.

本文引用的文献

1
Management of patients with atrial fibrillation (compilation of 2006 ACCF/AHA/ESC and 2011 ACCF/AHA/HRS recommendations): a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.心房颤动患者的管理(2006年美国心脏病学会基金会/美国心脏协会/欧洲心脏病学会及2011年美国心脏病学会基金会/美国心脏协会/心律学会推荐意见汇编):美国心脏病学会/美国心脏协会实践指南工作组报告
J Am Coll Cardiol. 2013 May 7;61(18):1935-44. doi: 10.1016/j.jacc.2013.02.001. Epub 2013 Apr 1.
2
Anatomical basis of minimally invasive epicardial ablation of atrial fibrillation.经胸微创心外膜消融治疗心房颤动的解剖学基础。
Eur J Cardiothorac Surg. 2013 Apr;43(4):673-82. doi: 10.1093/ejcts/ezs550. Epub 2012 Oct 30.
3
2012 HRS/EHRA/ECAS expert consensus statement on catheter and surgical ablation of atrial fibrillation: recommendations for patient selection, procedural techniques, patient management and follow-up, definitions, endpoints, and research trial design: a report of the Heart Rhythm Society (HRS) Task Force on Catheter and Surgical Ablation of Atrial Fibrillation. Developed in partnership with the European Heart Rhythm Association (EHRA), a registered branch of the European Society of Cardiology (ESC) and the European Cardiac Arrhythmia Society (ECAS); and in collaboration with the American College of Cardiology (ACC), American Heart Association (AHA), the Asia Pacific Heart Rhythm Society (APHRS), and the Society of Thoracic Surgeons (STS). Endorsed by the governing bodies of the American College of Cardiology Foundation, the American Heart Association, the European Cardiac Arrhythmia Society, the European Heart Rhythm Association, the Society of Thoracic Surgeons, the Asia Pacific Heart Rhythm Society, and the Heart Rhythm Society.2012年心房颤动导管消融与外科消融专家共识声明:患者选择、手术技术、患者管理与随访、定义、终点及研究试验设计的建议:心律学会(HRS)心房颤动导管消融与外科消融特别工作组报告。与欧洲心脏病学会(ESC)注册分支欧洲心律协会(EHRA)及欧洲心脏心律失常学会(ECAS)合作制定;并与美国心脏病学会(ACC)、美国心脏协会(AHA)、亚太心律学会(APHRS)和胸外科医师学会(STS)协作。得到美国心脏病学会基金会、美国心脏协会、欧洲心脏心律失常学会、欧洲心律协会、胸外科医师学会、亚太心律学会和心律学会管理机构的认可。
Heart Rhythm. 2012 Apr;9(4):632-696.e21. doi: 10.1016/j.hrthm.2011.12.016. Epub 2012 Mar 1.
4
Treatment of lone atrial fibrillation: a look at the past, a view of the present and a glance at the future.孤立性心房颤动的治疗:回顾过去,着眼现在,展望未来。
Eur J Cardiothorac Surg. 2012 Jun;41(6):1284-94. doi: 10.1093/ejcts/ezr222. Epub 2012 Jan 10.
5
Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC).心房颤动管理指南:欧洲心脏病学会(ESC)心房颤动管理特别工作组
Europace. 2010 Oct;12(10):1360-420. doi: 10.1093/europace/euq350.
6
A prospective randomized multicenter comparison on health-related quality of life: the value of add-on arrhythmia surgery in patients with paroxysmal, permanent or persistent atrial fibrillation undergoing valvular and/or coronary bypass surgery.前瞻性随机多中心比较生活质量相关:在瓣膜和/或冠状动脉旁路手术治疗阵发性、永久性或持续性心房颤动患者中附加心律失常手术的价值。
J Cardiovasc Electrophysiol. 2010 May;21(5):511-20. doi: 10.1111/j.1540-8167.2009.01655.x. Epub 2009 Nov 17.
7
Real-life anticoagulation treatment of atrial fibrillation after catheter ablation: Possible overtreatment of low-risk patients.导管消融术后心房颤动的真实世界抗凝治疗:低危患者可能过度治疗。
Thromb Haemost. 2009 Oct;102(4):754-8. doi: 10.1160/TH09-03-0184.
8
Use and underuse of oral anticoagulation for stroke prevention in atrial fibrillation: old and new paradigms.口服抗凝药在预防心房颤动卒中中的应用和不足:旧与新的模式。
Semin Thromb Hemost. 2009 Sep;35(6):554-9. doi: 10.1055/s-0029-1241048. Epub 2009 Sep 28.
9
Bleeding risk during oral anticoagulation in atrial fibrillation patients older than 80 years.80岁以上心房颤动患者口服抗凝治疗期间的出血风险。
J Am Coll Cardiol. 2009 Sep 8;54(11):999-1002. doi: 10.1016/j.jacc.2009.05.046.
10
Female gender is a risk factor for stroke and thromboembolism in atrial fibrillation patients.女性性别是心房颤动患者发生中风和血栓栓塞的一个危险因素。
Thromb Haemost. 2009 May;101(5):802-5.

房颤患者同期消融术后抗栓治疗的指南依从性

Guideline adherence in antithrombotic treatment after concomitant ablation surgery in atrial fibrillation patients.

作者信息

van Breugel Henrica N A M, Gelsomino Sandro, Lozekoot Pieter W J, Accord Ryan E, Lucà Fabiana, Parise Orlando, Crijns Harry J G M, Maessen Jos G

机构信息

Cardiothoracic Surgery and Cardiology, University Hospital, Maastricht, Netherlands.

出版信息

Interact Cardiovasc Thorac Surg. 2014 Mar;18(3):313-20. doi: 10.1093/icvts/ivt522. Epub 2013 Dec 13.

DOI:10.1093/icvts/ivt522
PMID:24336783
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3930226/
Abstract

OBJECTIVES

We investigated real-life oral anticoagulation (OAC) treatment after surgical ablation and examined its adherence to current recommendations. We also explored factors related to OAC use preoperatively and at follow-up.

METHODS

One hundred and fifteen patients with atrial fibrillation (AF) were evaluated during 12-month follow-up after surgery. Patients were divided into two categories according to the congestive heart failure, hypertension, age ≥75 years, diabetes and prior stroke [or transient ischaemic attack or thromboembolism] (CHADS2) score: 60 patients were assigned to the high-risk group (CHADS2 score ≥2) and 55 to the low-risk group (CHADS2 score ≤1). OAC use was defined as guideline adherent, undertreatment or overtreatment.

RESULTS

Baseline overall guideline adherence was 62%. OAC was underprescribed in high-risk patients and overprescribed in low-risk patients (both, P < 0.001). The only factor associated with OAC use after logistic regression analysis were age >75 years (P = 0.01) and preoperative AF > paroxysmal (P = 0.013). Overall guideline adherence at 12-month follow-up showed a trend towards a better adherence in the sinus rhythm (SR) subgroup (74% vs 55%, P = 0.02). OAC was underprescribed in high-risk patients and overprescribed in low-risk patients (both P < 0.001). After logistic regression analysis, preoperative OAC use (P = 0.007) and other indications for OAC (P = 0.01) were predictors of anticoagulation treatment.

CONCLUSIONS

Real-life OAC prescription in AF patients showed a moderate guideline adherence, with high-risk patients being undertreated and low-risk patients being overtreated. These findings stress the importance that antithrombotic treatment in patients undergoing AF surgery needs to be critically re-evaluated.

摘要

目的

我们调查了手术消融术后的实际口服抗凝(OAC)治疗情况,并检查了其对当前建议的遵循情况。我们还探讨了术前和随访时与使用OAC相关的因素。

方法

115例房颤(AF)患者在术后12个月的随访期间接受评估。根据充血性心力衰竭、高血压、年龄≥75岁、糖尿病和既往卒中[或短暂性脑缺血发作或血栓栓塞](CHADS2)评分将患者分为两类:60例患者被分配到高危组(CHADS2评分≥2),55例患者被分配到低危组(CHADS2评分≤1)。OAC的使用被定义为符合指南、治疗不足或治疗过度。

结果

基线时总体指南遵循率为62%。高危患者OAC处方不足,低危患者OAC处方过度(均P<0.001)。逻辑回归分析后,与使用OAC相关的唯一因素是年龄>75岁(P=0.01)和术前房颤>阵发性房颤(P=0.013)。12个月随访时的总体指南遵循率显示,窦性心律(SR)亚组有更好的遵循趋势(74%对55%,P=0.02)。高危患者OAC处方不足,低危患者OAC处方过度(均P<0.001)。逻辑回归分析后,术前使用OAC(P=0.007)和OAC的其他指征(P=0.01)是抗凝治疗的预测因素。

结论

房颤患者的实际OAC处方显示出对指南的适度遵循,高危患者治疗不足,低危患者治疗过度。这些发现强调了对接受房颤手术患者的抗血栓治疗进行严格重新评估的重要性。